BACKGROUND: The long term outcome of children entered into neonatal trials of high frequency oscillatory ventilation (HFOV) or conventional ventilation (CV) has been rarely studied. OBJECTIVE: To evaluate respiratory and neurodevelopmental outcomes for children entered into the United Kingdom Oscillation Study, which was designed to evaluate these outcomes. METHODS: Surviving infants were followed until 2 years of age corrected for prematurity. Study forms were completed by local paediatricians at routine assessments, and parents were asked to complete a validated neurodevelopmental questionnaire. RESULTS: Paediatricians' forms were returned for 73% of the 585 surviving infants. Respiratory symptoms were common in all infants, and 41% had received inhaled medication. Mode of ventilation had no effect on frequency of any symptoms. At 24 months of age, severe neurodevelopmental disability was present in 9% and other disabilities in 38% of children, but the prevalence of disability was similar in children who received HFOV or CV (relative risk 0.93; 95% confidence interval 0.74 to 1.16). The prevalence of disability did not vary by gestational age, but boys were more likely to have overall disability. Developmental scores were unaffected by mode of ventilation (relative risk 1.13; 95% confidence interval 0.78 to 1.63) and were lower in infants born before 26 weeks gestation compared with babies born at 26-28 weeks. CONCLUSIONS: Initial mode of ventilation in very preterm infants has no impact on respiratory or neurodevelopmental morbidity at 2 years. HFOV and CV appear equally effective for the early treatment of respiratory distress syndrome.
RCT Entities:
BACKGROUND: The long term outcome of children entered into neonatal trials of high frequency oscillatory ventilation (HFOV) or conventional ventilation (CV) has been rarely studied. OBJECTIVE: To evaluate respiratory and neurodevelopmental outcomes for children entered into the United Kingdom Oscillation Study, which was designed to evaluate these outcomes. METHODS: Surviving infants were followed until 2 years of age corrected for prematurity. Study forms were completed by local paediatricians at routine assessments, and parents were asked to complete a validated neurodevelopmental questionnaire. RESULTS: Paediatricians' forms were returned for 73% of the 585 surviving infants. Respiratory symptoms were common in all infants, and 41% had received inhaled medication. Mode of ventilation had no effect on frequency of any symptoms. At 24 months of age, severe neurodevelopmental disability was present in 9% and other disabilities in 38% of children, but the prevalence of disability was similar in children who received HFOV or CV (relative risk 0.93; 95% confidence interval 0.74 to 1.16). The prevalence of disability did not vary by gestational age, but boys were more likely to have overall disability. Developmental scores were unaffected by mode of ventilation (relative risk 1.13; 95% confidence interval 0.78 to 1.63) and were lower in infants born before 26 weeks gestation compared with babies born at 26-28 weeks. CONCLUSIONS: Initial mode of ventilation in very preterm infants has no impact on respiratory or neurodevelopmental morbidity at 2 years. HFOV and CV appear equally effective for the early treatment of respiratory distress syndrome.
Authors: G Moriette; J Paris-Llado; H Walti; B Escande; J F Magny; G Cambonie; G Thiriez; S Cantagrel; T Lacaze-Masmonteil; L Storme; T Blanc; J M Liet; C André; B Salanave; G Bréart Journal: Pediatrics Date: 2001-02 Impact factor: 7.124
Authors: Alice H Johnson; Janet L Peacock; Anne Greenough; Neil Marlow; Elizabeth S Limb; Louise Marston; Sandra A Calvert Journal: N Engl J Med Date: 2002-08-29 Impact factor: 91.245
Authors: Sherry E Courtney; David J Durand; Jeanette M Asselin; Mark L Hudak; Judy L Aschner; Craig T Shoemaker Journal: N Engl J Med Date: 2002-08-29 Impact factor: 91.245
Authors: Samantha Johnson; Neil Marlow; Dieter Wolke; Leslie Davidson; Louise Marston; Ann O'Hare; Janet Peacock; Jane Schulte Journal: Dev Med Child Neurol Date: 2004-06 Impact factor: 5.449
Authors: T Lacaze-Masmonteil; P Truffert; D Pinquier; P Daoud; G Goldfarb; E Vicaut; B Fauroux Journal: Arch Dis Child Date: 2004-06 Impact factor: 3.791
Authors: Mark R Thomas; Gerrard F Rafferty; Elizabeth S Limb; Janet L Peacock; Sandra A Calvert; Neil Marlow; Anthony D Milner; Anne Greenough Journal: Am J Respir Crit Care Med Date: 2003-12-23 Impact factor: 21.405
Authors: K Telford; L Waters; H Vyas; B N Manktelow; E S Draper; N Marlow Journal: Arch Dis Child Fetal Neonatal Ed Date: 2006-08-11 Impact factor: 5.747
Authors: Richard B Parad; Jonathan M Davis; Jessica Lo; Mark Thomas; Neil Marlow; Sandy Calvert; Janet L Peacock; Anne Greenough Journal: Neonatology Date: 2015-03-03 Impact factor: 4.035
Authors: Yvonne E Vaucher; Myriam Peralta-Carcelen; Neil N Finer; Waldemar A Carlo; Marie G Gantz; Michele C Walsh; Abbot R Laptook; Bradley A Yoder; Roger G Faix; Abhik Das; Kurt Schibler; Wade Rich; Nancy S Newman; Betty R Vohr; Kimberly Yolton; Roy J Heyne; Deanne E Wilson-Costello; Patricia W Evans; Ricki F Goldstein; Michael J Acarregui; Ira Adams-Chapman; Athina Pappas; Susan R Hintz; Brenda Poindexter; Anna M Dusick; Elisabeth C McGowan; Richard A Ehrenkranz; Anna Bodnar; Charles R Bauer; Janell Fuller; T Michael O'Shea; Gary J Myers; Rosemary D Higgins Journal: N Engl J Med Date: 2012-12-27 Impact factor: 91.245
Authors: Samantha Johnson; Sarah E Seaton; Bradley N Manktelow; Lucy K Smith; David Field; Elizabeth S Draper; Neil Marlow; Elaine M Boyle Journal: BMC Res Notes Date: 2014-04-08
Authors: Gordon Qin; Jessica W Lo; Neil Marlow; Sandy A Calvert; Anne Greenough; Janet L Peacock Journal: PLoS One Date: 2017-07-19 Impact factor: 3.240